Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Cardinal Health Inc ha un obiettivo di prezzo di consenso pari a $148.37, stabilito in base alle ultime valutazioni degli analisti di 19. Le ultime 3 valutazioni degli analisti sono state rilasciate da Wells Fargo, Evercore ISI Group y Baird il agosto 13, 2025. Con un obiettivo di prezzo medio di $192.67 tra le Wells Fargo, Evercore ISI Group y Baird, c'è un implicito 23.33% upside per Cardinal Health Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Wells Fargo
Evercore ISI Group
Baird
Leerink Partners
Morgan Stanley
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Cardinal Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/13/2025 | 18.42% | Wells Fargo | $183 → $185 | Maintains | Overweight | |||
08/13/2025 | 21.62% | Evercore ISI Group | $200 → $190 | Maintains | Outperform | |||
08/13/2025 | 29.94% | Baird | $197 → $203 | Maintains | Outperform | |||
08/12/2025 | 19.06% | Leerink Partners | $188 → $186 | Maintains | Outperform | |||
07/16/2025 | 21.62% | Morgan Stanley | $181 → $190 | Maintains | Overweight | |||
06/13/2025 | 15.86% | Morgan Stanley | $166 → $181 | Maintains | Overweight | |||
06/13/2025 | 8.82% | Citigroup | $157 → $170 | Maintains | Neutral | |||
06/12/2025 | 15.22% | Evercore ISI Group | $175 → $180 | Maintains | Outperform | |||
06/10/2025 | 8.82% | B of A Securities | $165 → $170 | Maintains | Buy | |||
06/03/2025 | 14.58% | Wells Fargo | $136 → $179 | Upgrade | Equal-Weight → Overweight | |||
06/02/2025 | 12.02% | Evercore ISI Group | $165 → $175 | Maintains | Outperform | |||
05/05/2025 | 6.26% | Morgan Stanley | $142 → $166 | Maintains | Overweight | |||
05/02/2025 | 8.82% | UBS | $160 → $170 | Maintains | Buy | |||
05/02/2025 | 8.82% | Baird | $156 → $170 | Maintains | Outperform | |||
05/01/2025 | 0.5% | Citigroup | $140 → $157 | Maintains | Neutral | |||
04/29/2025 | 2.42% | UBS | $150 → $160 | Maintains | Buy | |||
04/17/2025 | -10.38% | Citigroup | $130 → $140 | Maintains | Neutral | |||
04/11/2025 | -0.78% | B of A Securities | $150 → $155 | Maintains | Buy | |||
03/31/2025 | -3.98% | Mizuho | $142 → $150 | Maintains | Outperform | |||
02/05/2025 | -3.98% | Jefferies | $140 → $150 | Upgrade | Hold → Buy | |||
02/04/2025 | -7.18% | JP Morgan | $142 → $145 | Maintains | Neutral | |||
02/04/2025 | -12.94% | Wells Fargo | $135 → $136 | Maintains | Equal-Weight | |||
01/31/2025 | -16.78% | Citigroup | $129 → $130 | Maintains | Neutral | |||
01/31/2025 | -9.1% | Morgan Stanley | $136 → $142 | Maintains | Overweight | |||
01/29/2025 | -13.58% | Wells Fargo | $127 → $135 | Maintains | Equal-Weight | |||
01/24/2025 | -9.1% | JP Morgan | $132 → $142 | Maintains | Neutral | |||
01/10/2025 | -17.42% | Citigroup | $120 → $129 | Maintains | Neutral | |||
01/08/2025 | -7.82% | TD Cowen | $130 → $144 | Upgrade | Hold → Buy | |||
01/07/2025 | -10.38% | Evercore ISI Group | $140 → $140 | Upgrade | In-Line → Outperform | |||
01/06/2025 | -7.18% | B of A Securities | $132 → $145 | Upgrade | Neutral → Buy | |||
12/17/2024 | -12.94% | Morgan Stanley | $127 → $136 | Maintains | Overweight | |||
12/13/2024 | -18.7% | Wells Fargo | $101 → $127 | Upgrade | Underweight → Equal-Weight | |||
11/27/2024 | -19.98% | Jefferies | $110 → $125 | Maintains | Hold | |||
11/04/2024 | -18.7% | Morgan Stanley | $119 → $127 | Maintains | Overweight | |||
11/04/2024 | -20.62% | Deutsche Bank | $119 → $124 | Maintains | Hold | |||
11/04/2024 | -11.02% | UBS | $134 → $139 | Maintains | Buy | |||
11/04/2024 | -23.19% | Mizuho | $110 → $120 | Maintains | Neutral | |||
11/04/2024 | -14.86% | Barclays | $117 → $133 | Maintains | Overweight | |||
10/22/2024 | -14.22% | UBS | $125 → $134 | Maintains | Buy | |||
09/11/2024 | -19.98% | Argus Research | $115 → $125 | Maintains | Buy | |||
08/21/2024 | -21.26% | JP Morgan | $111 → $123 | Maintains | Neutral | |||
08/16/2024 | -23.83% | Deutsche Bank | $115 → $119 | Maintains | Hold | |||
08/15/2024 | -19.98% | UBS | $120 → $125 | Maintains | Buy | |||
08/15/2024 | -35.35% | Wells Fargo | $95 → $101 | Maintains | Underweight | |||
08/15/2024 | -23.83% | Morgan Stanley | $114 → $119 | Maintains | Overweight | |||
08/15/2024 | -26.39% | Evercore ISI Group | $105 → $115 | Maintains | In-Line | |||
08/15/2024 | -12.3% | Baird | $130 → $137 | Maintains | Outperform | |||
07/19/2024 | -31.51% | Citigroup | $115 → $107 | Maintains | Neutral | |||
07/09/2024 | -32.79% | Evercore ISI Group | $115 → $105 | Maintains | In-Line | |||
07/09/2024 | -16.78% | Baird | $129 → $130 | Maintains | Outperform | |||
05/15/2024 | -26.39% | Argus Research | $120 → $115 | Maintains | Buy | |||
05/06/2024 | -29.59% | Deutsche Bank | $116 → $110 | Maintains | Hold | |||
05/03/2024 | -26.39% | Evercore ISI Group | $110 → $115 | Maintains | In-Line | |||
05/03/2024 | -18.06% | Baird | $134 → $128 | Maintains | Outperform | |||
04/29/2024 | -39.83% | Wells Fargo | $96 → $94 | Maintains | Underweight | |||
02/26/2024 | -19.98% | Leerink Partners | → $125 | Initiates | → Outperform | |||
02/09/2024 | — | Argus Research | — | Upgrade | Hold → Buy | |||
02/05/2024 | -19.98% | UBS | $122 → $125 | Maintains | Buy | |||
01/29/2024 | -21.91% | UBS | $114 → $122 | Maintains | Buy | |||
01/03/2024 | -25.11% | Barclays | → $117 | Initiates | → Overweight | |||
12/14/2023 | -38.55% | Wells Fargo | → $96 | Initiates | → Underweight | |||
11/17/2023 | -28.31% | JP Morgan | $101 → $112 | Maintains | Neutral | |||
11/09/2023 | -32.79% | Deutsche Bank | $102 → $105 | Maintains | Hold | |||
11/06/2023 | -33.43% | Mizuho | $95 → $104 | Maintains | Neutral | |||
08/17/2023 | -34.71% | Deutsche Bank | $90 → $102 | Maintains | Hold | |||
08/16/2023 | -42.39% | TD Cowen | $88 → $90 | Maintains | Market Perform | |||
08/16/2023 | -35.35% | JP Morgan | $93 → $101 | Maintains | Neutral | |||
08/16/2023 | -35.99% | Morgan Stanley | $92 → $100 | Maintains | Overweight | |||
08/16/2023 | -30.87% | Baird | $107 → $108 | Maintains | Outperform | |||
08/16/2023 | -38.55% | Mizuho | $94 → $96 | Maintains | Neutral | |||
07/11/2023 | -39.83% | Mizuho | $85 → $94 | Maintains | Neutral | |||
07/10/2023 | -35.99% | Evercore ISI Group | → $100 | Downgrade | Outperform → In-Line | |||
06/12/2023 | -42.39% | Citigroup | $88 → $90 | Maintains | Neutral | |||
06/12/2023 | -45.59% | Barclays | $80 → $85 | Maintains | Equal-Weight | |||
06/12/2023 | -35.99% | Credit Suisse | $90 → $100 | Maintains | Neutral | |||
06/12/2023 | -37.91% | UBS | $93 → $97 | Maintains | Buy | |||
06/09/2023 | -40.47% | JP Morgan | $90 → $93 | Maintains | Neutral | |||
05/08/2023 | -43.67% | Citigroup | $77 → $88 | Maintains | Neutral | |||
05/08/2023 | -42.39% | Deutsche Bank | $88 → $90 | Maintains | Hold | |||
05/05/2023 | -43.67% | Barclays | $77 → $88 | Maintains | Equal-Weight | |||
04/26/2023 | -43.67% | Deutsche Bank | $77 → $88 | Maintains | Hold | |||
03/31/2023 | -50.71% | Citigroup | → $77 | Initiates | → Neutral | |||
03/22/2023 | -50.71% | Deutsche Bank | $82 → $77 | Maintains | Hold | |||
02/03/2023 | -41.11% | Credit Suisse | $89 → $92 | Maintains | Neutral | |||
02/03/2023 | -42.39% | Morgan Stanley | $86 → $90 | Maintains | Overweight | |||
02/03/2023 | -39.83% | Baird | $87 → $94 | Upgrade | Neutral → Outperform | |||
01/31/2023 | -41.75% | UBS | $78 → $91 | Maintains | Buy | |||
01/06/2023 | -44.95% | Morgan Stanley | $82 → $86 | Maintains | Overweight | |||
11/22/2022 | -49.43% | Credit Suisse | $64 → $79 | Maintains | Neutral | |||
11/14/2022 | -52.63% | Mizuho | $66 → $74 | Maintains | Neutral | |||
11/07/2022 | -47.51% | Morgan Stanley | $76 → $82 | Maintains | Overweight | |||
11/07/2022 | -47.51% | Baird | $74 → $82 | Maintains | Neutral | |||
11/04/2022 | -48.79% | B of A Securities | $64 → $80 | Upgrade | Underperform → Neutral |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Cardinal Health (CAH)?
El último precio objetivo de Cardinal Health (NYSE:CAH) fue comunicado por Wells Fargo el agosto 13, 2025. La firma de analistas fijó un precio objetivo para $185.00 que espera CAH a rise dentro de 12 meses (un posible 18.42% upside). 39 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Cardinal Health (CAH)?
La última calificación de analistas para Cardinal Health (NYSE:CAH) fue proporcionada por Wells Fargo, y Cardinal Health mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Cardinal Health (CAH)?
La última revisión al alza de Cardinal Health Inc se produjo en junio 3, 2025, cuando Wells Fargo elevó su precio objetivo a $179. Wells Fargo anteriormente tenía an equal-weight para Cardinal Health Inc.
¿Cuándo fue la última revisión a la baja de Cardinal Health (CAH)?
La última revisión a la baja de Cardinal Health Inc se produjo en julio 10, 2023, cuando Evercore ISI Group cambió su precio objetivo de N/A a $100 para Cardinal Health Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Cardinal Health (CAH)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Cardinal Health, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Cardinal Health se registró el agosto 13, 2025, por lo que la próxima calificación estará disponible en torno al agosto 13, 2026.
¿Es correcta la calificación de los analistas sobre Cardinal Health (CAH)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Cardinal Health (CAH) fue un mantuvo con un precio objetivo de $183.00 a $185.00. El precio actual al que cotiza Cardinal Health (CAH) es de $156.22, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.